2. Search Result
Search Result
Results for "

C57BL6/J mouse

" in MedChemExpress (MCE) Product Catalog:

2717

Inhibitors & Agonists

1

Screening Libraries

11

Fluorescent Dye

26

Biochemical Assay Reagents

253

Peptides

19

MCE Kits

406

Inhibitory Antibodies

269

Natural
Products

2073

Recombinant Proteins

64

Isotope-Labeled Compounds

49

Antibodies

6

Click Chemistry

755

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-117427
    D5D-IN-326

    		Others Metabolic Disease
    D5D-IN-326 is a selective, orally active delta-5 desaturase (D5D) inhibitor, with IC50s of 72 and 22 nM for rat and human D5D in enzymic and cell-based assays, respectively, has no effect on D6D or D9D activity. D5D-IN-326 reduces insulin resistance and decreases body weight in diet-induced obese C57BL/6J mice .
    D5D-IN-326
  • HY-103360
    J-113863
    3 Publications Verification

    		 CCR Inflammation/Immunology
    J-113863 is a potent and selective CCR1 antagonist with IC50 values of 0.9 nM and 5.8 nM for human and mouse CCR1 receptors, respectively. J-113863 is also a potent antagonist of the human CCR3 (IC50 of 0.58 nM) , but a weak antagonist of the mouse CCR3 (IC50 of 460 nM). J-113863 is inactive against CCR2, CCR4 and CCR5, as well as the LTB4 or TNF-α receptors. Anti-inflammatory effect .
    J-113863
  • HY-160025
    IDO antagonist-1

    		Indoleamine 2,3-Dioxygenase (IDO) Cancer
    IDO antagonist-1 (compound 163) is an antagonist of IDO . IDO antagonist-1 inhibits pancreatic adenocarcinoma cells growth in C57BL/6 mice .
    IDO antagonist-1
  • HY-157429
    25N-N1-Nap

    		5-HT Receptor Neurological Disease
    25N-N1-Nap (compound 16) is a β-arrestin-biased 5-HT2A agonist. 25N-N1-Nap antagonizes phencyclidine induced hyperactivity in Male C57BL/6 J mice .
    25N-N1-Nap
  • HY-168081
    PD-1/PD-L1-IN-52

    		PD-1/PD-L1 Cancer
    PD-1/PD-L1-IN-52 (Compound III-5) is an orally active PD-1/PD-L1 inhibitor that blocks the interaction between PD-1 and PD-L1, with an IC50 of 109.9 nM. PD-1/PD-L1-IN-52 exhibits antitumor activity in a C57BL/6 mouse xenograft model implanted with human PD-1-expressing MC38 colon cancer cells, with a TGI of 49.6% .
    PD-1/PD-L1-IN-52
  • HY-128435
    2,4'-Dihydroxybenzophenone-1

    		Others Metabolic Disease
    2,4'-Dihydroxybenzophenone ((Z)-SU4312) exhibited estrogenic activities. 2,4'-Dihydroxybenzophenone has oral bioactivity that can effectively protect C57BL/6J mice from Acetaminophen (HY-66005, APAP)-induced hepatotoxicity .
    2,4'-Dihydroxybenzophenone-1
  • HY-144743
    ATX inhibitor 12

    		Phosphodiesterase (PDE) Others
    ATX inhibitor 12 (compound 20) is an orally active and potent ATX (autotaxin) inhibitor, with an IC50 of 1.72 nM. ATX inhibitor 12 effectively alleviates lung structural damage with fewer fibrotic lesions at an oral dose of 60 mg/kg in C57Bl/6J mice. ATX inhibitor 12 can be uesd for idiopathic pulmonary fibrosis (IPF) research .
    ATX inhibitor 12
  • HY-N12375
    Kadsuphilin J

    		Others Others
    Kadsuphilin J is a lignan isolated from the roots of K. longipedunculata
    Kadsuphilin J
  • HY-P5169
    LVGRQLEEFL (mouse)

    		Amino Acid Derivatives Inflammation/Immunology
    LVGRQLEEFL (mouse) can be named as G * peptide, corresponding to amino acids 113 to 122 in apolipoprotein J ([113,122] apoJ)}. LVGRQLEEFL (mouse) exhibits anti-inflammatory and anti-atherogenic properties. LVGRQLEEFL (mouse) can be added to an apoJ mimetic, to form HM-10/10 peptide, which is a mimetic peptide and a novel chimeric high density lipoprotein. HM-10/10 peptide protects retinal pigment epithelium (RPE) and photoreceptors from oxidant induced cell death .
    LVGRQLEEFL (mouse)
  • HY-P5169A
    LVGRQLEEFL (mouse) (TFA)

    		Amino Acid Derivatives Inflammation/Immunology
    LVGRQLEEFL (mouse) TFA can be named as G * peptide, corresponding to amino acids 113 to 122 in apolipoprotein J ([113,122] apoJ)}. LVGRQLEEFL (mouse) TFA exhibits anti-inflammatory and anti-atherogenic properties. LVGRQLEEFL (mouse) TFA can be added to an apoJ mimetic, to form HM-10/10 peptide, which is a mimetic peptide and a novel chimeric high density lipoprotein. HM-10/10 peptide protects retinal pigment epithelium (RPE) and photoreceptors from oxidant induced cell death .
    LVGRQLEEFL (mouse) (TFA)
  • HY-110216
    5J-4

    		CRAC Channel Inflammation/Immunology
    5J-4 is a potent CRAC inhibitor. 5J-4 decreases the numbers of infiltrated mononuclear cell into the CNS, and significantly decreases the population of infiltrated CD4+ population. 5J-4 reduces the symptoms and delayed the onset of EAE (experimental autoimmune encephalomyelitis) in mouse model of inflammation .
    5J-4
  • HY-155172
    ZX-J-19j

    		Cyclophilin Cancer
    ZX-J-19j (Compound ZX-J-19j) is a cyclophilin J inhibitor. ZX-J-19j showes potent antitumor activity .
    ZX-J-19j
  • HY-19301
    J 104871

    J-104135

    		 Farnesyl Transferase Cancer
    J 104871 (J-104135) is a farnesyl pyrophosphate (FPP)-competitive farnesyltransferase (FTase) inhibitor. J 104871 inhibits rat brain FTase with an IC50 of 3.9 nM in the presence of farnesyl pyrophosphate (FPP) .
    J 104871
  • HY-145855
    J-1063

    		TGF-β Receptor Inflammation/Immunology
    J-1063 is a potent, selective and orally active ALK5 inhibitor with an IC50 of 0.039 µM. J-1063 shows anti-fibrotic effect by the inhibition of inflammatory infiltration, collagen deposition, and hepatocytes necrosis. J-1063 has the potential for the research of liver fibrosis .
    J-1063
  • HY-129826
    J-104129

    		mAChR Others
    J-104129 is a selective and orally active muscarinic M3 receptor antagonist (Ki = 4.2 nM). J-104129 is effective in promoting bronchodilation .
    J-104129
  • HY-163429
    J-1149

    		TGF-β Receptor p38 MAPK Inflammation/Immunology Cancer
    J-1149 is a potent ALK5 inhibitor, with an IC50 value of 0.017 μM. J-1149 also shows weak p38α MAP kinase inhibitory activity, with an IC50 value of 0.435 μM. J-1149 can be used for liver fibrosis research .
    J-1149
  • HY-107653
    J 104129 fumarate

    		mAChR Neurological Disease
    J 104129 fumarate is a selective and orally active muscarinic M3 antagonist with Ki values of 4.2 nM and 490 nM for M3 and M2, respectively. J 104129 fumarate antagonized ACh-induced bronchoconstriction. J 104129 fumarate has the potential for the research of obstructive airway disease .
    J 104129 fumarate
  • HY-107721
    (±)-J-113397

    		Opioid Receptor Neurological Disease
    (±)-J-113397 is a potent and selective non-peptidyl ORL1 receptor antagonist with a Ki of 1.8 nM for cloned human ORL1. J-113397 inhibited nociceptin/orphanin FQ-stimulated GTPγS binding to CHO cells expressing ORL1 with an IC50 value of 5.3 nM. J-113397 can be used for researching the physiological roles of nociceptin/orphanin FQ .
    (±)-J-113397
  • HY-149403
    J-1048

    		Anaplastic lymphoma kinase (ALK) Others
    J-1048 is an activin receptor-like kinase 5 (ALK5) inhibitor. J-1048 can inhibit TAA-induced liver fibrosis in mice by explicitly blocking the TGF-β/Smad signaling pathway .
    J-1048
  • HY-118809
    J 2931

    NSC 321569; J 2532

    		 Others Others
    J 2931 is an active compound.
    J 2931
  • HY-114072A
    (S,S)-J-113397

    		Opioid Receptor Neurological Disease
    (S,S)-J-113397 is an isomer of J-113397 (HY-114072). J-113397 is an Opioid Receptor antagonist .
    (S,S)-J-113397
  • HY-103360A
    cis-J-113863

    UCB35625

    		 CCR Inflammation/Immunology
    cis-J-113863 is a competitive chemokine receptor 1 (CCR1) antagonist, with IC50 values of 0.9 and 5.8 nM for human and mouse CCR1 receptors, respectively .
    cis-J-113863
  • HY-126873
    Nikkomycin J

    		Others Others
    Nikkomycin J is an active compound. Nikkomycin J can be used for various researches .
    Nikkomycin J
  • HY-149714
    J6-3

    		ICMT Cancer
    J6-3 is an inhibitor of ICMT with an IC50 of 0.6 μM and has anticancer activity. J6-3 inhibits MDA-MB231 cells with an IC50 of 3.4 μM .
    J6-3
  • HY-13779A
    J147

    		Monoamine Oxidase Dopamine Transporter Neurological Disease
    J147 is an exceptionally potent, orally active, neuroprotective agent for cognitive enhancement. J147 can pass the blood brain barrier (BBB). J147 can inhibit monoamine oxidase B (MAO B) and the dopamine transporter. J147 plays an impotant role in Alzheimer’s disease (AD) .
    J147
  • HY-111615
    J-2156

    		Somatostatin Receptor Neurological Disease
    J-2156 is a high potent, selective somatostatin receptor type 4 (SST4 receptor) agonist with IC50s of 0.05 nM and 0.07 nM for human and rat SST4 receptors, respectively. J-2156 is used for the relief of mechanical allodynia and mechanical hyperalgesia in the ipsilateral hindpaws in rats .
    J-2156
  • HY-155699
    J27644

    		HDAC Inflammation/Immunology
    J27644 is a potent HDAC inhibitor. J27644 mitigates TGF-β-induced pulmonary fibrosis .
    J27644
  • HY-122021
    J-115814

    		Neuropeptide Y Receptor Neurological Disease
    J-115814 is a potent and selective neuropeptide Y1 antagonist with Ki values of 1.4, 1.8, 1.9, >10000, 620, 6000, >10000 nM for hY1, rY1, mY1, hY2, hY4, hY5, mY6, respectively. J-115814 inhibits feeding behaviors .
    J-115814
  • HY-113366S
    Prostaglandin J2-d4

    		Isotope-Labeled Compounds Others
    Prostaglandin J2-d4 is the deuterium labeled Prostaglandin J2[1].
    Prostaglandin J2-d4
  • HY-N13315
    Otophylloside J

    		Others Neurological Disease
    Otophylloside J is a pregnane glycosides isolated from the roots of Cynanchum otophyllum. Otophylloside J can be used in epilepsy research .
    Otophylloside J
  • HY-N12137
    Glycoside St-J

    		Others Cancer
    Glycoside St-J (Compound 2) is a triterpenoid saponin. Glycoside St-J has antitumor activity and inhibits HeLa cell proliferation. Glycoside St-J Isolates from natural Anemone flaccida. Glycoside St-J can be used in the development of new anticancer agents .
    Glycoside St-J
  • HY-119550
    J1075

    		HDAC Parasite Infection
    J1075 is a selective Schistosoma mansoni HDAC8 inhibitor (with decreased affinity for human HDAC8). J1075 can induce apoptosis (Apoptosis) and death in schistosome cells. J1075 holds research value in the field of anti-parasitic agents .
    J1075
  • HY-N9005
    Dysolenticin J

    		Others Cardiovascular Disease
    Dysolenticin J has potent vasodilative effects on aortic rings. Dysolenticin J is an alkaloid that can be isolated from Dysoxylum lenticellatum .
    Dysolenticin J
  • HY-15648H
    GSK-J5 hydrochloride

    		Others Cancer
    GSK-J5 hydrochloride is a cell-permeable ester derivative of GSK J2 (HY-15648A), inactive. GSK-J5 hydrochloride is also an isomer of GSK-J4 (HY-15648B) and often used as a negative group .
    GSK-J5 hydrochloride
  • HY-157269
    J10-1

    		Others Inflammation/Immunology
    J10-1 is a hapten. J10-1 promotes peptide exchange of all DR alleles (DR1, DR2, DR4 (DRB1*0401)) and promotes peptide binding to MHC II, which can be used in the study of immune regulation .
    J10-1
  • HY-N10899
    Bruceine J

    		Parasite Infection
    Bruceine J, a quassinoid, is a nature product that could be isolated from fruits of Br. jaVanica. Bruceine J has anti-Babesial activity .
    Bruceine J
  • HY-116129
    BPR1J-340

    		FLT3 Apoptosis Cancer
    BPR1J-340 is a potent FLT3 inhibitor with an IC50 of ~25 nM. BPR1J-340 inhibits the phosphorylation of FLT3 and STAT5 and triggered apoptosis in FLT3-ITD + acute myeloid leukemia (AML) cells. BPR1J-340 exhibits significant anti-tumor activities .
    BPR1J-340
  • HY-N12812
    Tenuifoliose J

    		Others Neurological Disease
    Tenuifoliose J is a neuroprotective oligosaccharide. Tenuifoliose J protects SY5Y cells induced by corticosterone (HY-B1618) .
    Tenuifoliose J
  • HY-N9312
    Ganoderic acid J

    		Others Inflammation/Immunology
    Ganoderic acid J is a natural terpenoid isolated from the Fungus Ganoderma lucidum. Ganoderic acid J possesses anti-inflammatory anti-inflammatory activity .
    Ganoderic acid J
  • HY-149713
    J1-1

    		ICMT Cancer
    J1-1 is an inhibitor of ICMT with an IC50 of 1.0 μM and has anticancer activity .
    J1-1
  • HY-112255
    J9

    		Others Cancer
    J9 is a small molecule that reverses Dexamethasone (HY-14648) resistance in T-cell acute lymphoblastic leukemia. J9 is lethal to CUTLL1 cells only in the presence of Dexamethasone. J9 inhibits CUTLL1 cell growth with an EC50 of 28 μM in combination with Dexamethasone .
    J9
  • HY-N12720
    Cynanoside J

    		Others Cancer
    Cynanoside J is a C21 steroidal glycosides that can be obtained from Cynanchum taihangense. The IC50 values of Cynanoside J for HL-60, THP1, and Caco2 are 6.38, 5.82, and 6.76 μM, respectively. Cynanoside J can be used in cancer research .
    Cynanoside J
  • HY-163535
    J208

    		HDAC DNA Methyltransferase Apoptosis Inflammation/Immunology Cancer
    J208 is a dual inhibitor for histone deacetylase (HDAC) and DNA methyltransferase (DNMT). J208 inhibits proliferation of cancer cells, as well as the migration/invasion of triple-negative breast cancer (TNBC) cells. J208 induces apoptosis, arrests the cell cycle at G0/G1 phase. J2008 activates the innate immune signalling pathway in TNBC, by inducing the expression of endogenous retroviruses (ERVs) .
    J208
  • HY-124653
    HSP27 inhibitor J2
    5 Publications Verification

    J2

    		 HSP Cancer
    HSP27 inhibitor J2 (J2) is a HSP27 inhibitor, which significantly induces abnormal HSP27 dimer formation and inhibits a production of HSP27 giant polymers, thereby having an effect of inhibiting a chaperone function of the HSP27 and reducing a cell protection function thereof. HSP27 inhibitor J2 (J2) remarkably enhances the antiproliferative activity of 17-AAG and sensitizes cisplatin-induced lung cancer cell growth inhibition .
    HSP27 inhibitor J2
  • HY-125838
    J30-8

    		JNK Neurological Disease
    J30-8 is a potent and isoform-selective inhibitor of c-Jun N-terminal kinase 3 (JNK3) with an IC50 of 40 nM, which 2500-fold isoform selectivity against JNK1α1 and JNK2α2. J30-8 exhibits neuroprotective activity in vitro and potential for the treatment of neurodegenerative diseases .
    J30-8
  • HY-111615A
    J-2156 TFA

    		Somatostatin Receptor Neurological Disease Inflammation/Immunology
    J-2156 TFA is a high potent, selective somatostatin receptor type 4 (SST4 receptor) agonist with IC50s of 0.05 nM and 0.07 nM for human and rat SST4 receptors, respectively. J-2156 TFA has anti-inflammatory activity and it is used for the relief of mechanical allodynia and mechanical hyperalgesia in the ipsilateral hindpaws in rats .
    J-2156 TFA
  • HY-N7298
    Derrisisoflavone J

    		Others Others
    Derrisisoflavone J is a natural product .
    Derrisisoflavone J
  • HY-N13575
    Gancaonin J

    		Others
    Gancaonin J is a natural product .
    Gancaonin J
  • HY-N9670
    Epimedonin J

    		Others Others
    Epimedonin J is a natural product .
    Epimedonin J
  • HY-15648I
    GSK-J2 sodium

    		Others Cancer
    GSK-J2 sodium is the sodium form of GSK-J2 (HY-15648A). GSK-J2 is an isomer of GSK-J1, and does not have any specific activity. GSK-J1 (HY-15648) is a potent inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A .
    GSK-J2 sodium

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: